There are currently 1973 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis
NCT06245109
Recruiting
This is a clinical trial of people who have pain due to knee osteoarthritis at Northwestern University Feinberg School of Medicine. The study will last for about 20 weeks. 180 qualified participants will be randomly assigned in a 1:1:1 ratio (60 participants per group) to one of three treatment groups: duloxetine, celecoxib, or placebo. Participants will have an Xray, knee MRI, brain MRI, blood draws, pain sensitivity testing, and asked to fill out questionnaires. The purpose of this study is to... Read More
Gender:
ALL
Ages:
41 years and above
Trial Updated:
07/23/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Knee Osteoarthritis
Register for Updates
Defining Treatment Outcomes and Genetic Architecture in Idiopathic Toe Walking*
NCT06305689
Recruiting
To compare and contrast the clinical, gait and parent-reported outcomes following either non-operative (casting) or operative treatment for children with idiopathic toe walking (ITW) and determine whether there are specific genes associated with ITW.
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
07/23/2024
Locations: Shriners Hospitals for Children, Chicago, Illinois
Conditions: Idiopathic Toe Walking
Register for Updates
Impact of Serial Bedside Video Calls on Stress Level in Parents of Infants Admitted to NICU
NCT06252883
Recruiting
The goal of this randomized prospective interventional study is to determine if serial bedside video calls w/audio feature to NICU parents in addition to the routine phone and/or bedside updates can reduce parental stress level. The main question it aims to answer is if the impact of audio-visual calls to nicu parents can improve parent-infant relationship in the form of reduced parental anxiety/stress level. Participants will be parents of infants admitted to NICU for more than seven (7) days.... Read More
Gender:
ALL
Ages:
Between 7 days and 60 days
Trial Updated:
07/23/2024
Locations: John H. Stroger Hospital of Cook County, Chicago, Illinois
Conditions: Stress
Register for Updates
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT03990896
Recruiting
This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
NCT04427293
Recruiting
This is single arm study of a window of opportunity in which participants with previously untreated triple negative breast cancers (TNBC) who are candidates for potentially curative surgery will receive lenvatinib 12 mg daily for 7 and pembrolizumab 200 mg IV on day 1 prior to surgery
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: University of Illinois, Chicago, Illinois
Conditions: Triple Negative Breast Cancer
Register for Updates
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
NCT00920972
Recruiting
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
07/19/2024
Locations: Children's Memorial Hospital, Chicago, Illinois
Conditions: Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
Register for Updates
Blood Pressure Variability and Ischemic Stroke Outcome
NCT05756257
Recruiting
The goal of this observational study is to evaluate the role of blood pressure (BPV) variability in patients suffering from acute ischemic stroke. The main questions it aims to answer are: 1. To determine the association of BPV with functional/cognitive outcome after ischemic stroke. 2. To determine a pathophysiologic mechanism of BPV's deleterious effect on functional outcome. 3. To evaluate potential treatment targets to pharmacologically reduce BPV after ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2024
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Acute Ischemic Stroke, Blood Pressure Variability
Register for Updates
Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis
NCT06516458
Recruiting
The purpose of this study is to develop a measurement of walking quality, called Gait Deviation Index (GDI) for people with Multiple Sclerosis (MS).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/18/2024
Locations: Shirley Ryan AbilityLab, Chicago, Illinois
Conditions: Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis Relapse, Multiple Sclerosis, Relapsing-Remitting
Register for Updates
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766
Recruiting
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: The University of Chicago Medical Center, Chicago, Illinois
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Register for Updates
Effect of Duramesh™ on Hernia Formation After Ileostomy Closure, Randomized Controlled Trial
NCT06511414
Recruiting
Diverting ileostomy is frequently utilized to protect high-risk anastomoses, though it is not shown to reduce the leak rate it may reduce the severe consequences of an anastomotic leak. Ileostomy will be reversed with restoration of continuity in majority of patients. Stoma site incisional hernias after ileostomy closure are complex hernias that can be associated with abdominal pain, discomfort, and a diminished quality of life. Duramesh™ non-absorbable polypropylene suture is a hollow core, mic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2024
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois
Conditions: Incisional Hernia, Ileostomy - Stoma
Register for Updates
A Novel Intervention for Weight Loss in Young Adults
NCT06230744
Recruiting
Obesity and cardiometabolic risks are significant public health issues, with about two-thirds of U.S. adults overweight or obese. Weight loss can prevent these health problems, but current lifestyle interventions have limited success. New, effective strategies are needed to address this rising issue at the population level. The goal of this clinical trial is to investigate how a behavioral intervention combined with technology impacts weight loss in young adults. The main questions it aims to an... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
07/16/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Weight Loss
Register for Updates
Progressive Abduction Loading Therapy
NCT04118998
Recruiting
This study attempts to minimize the development of a common movement impairment following stroke known as "flexion synergy" that makes it extremely difficult to reach outward with the arm. Participants with acute/subacute stroke will receive one of two study interventions in addition to prescribed therapies in both inpatient rehabilitation and day-rehab. Participants will be followed for 1 year.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/16/2024
Locations: Department of Physical Therapy and Human Movement Sciences, Chicago, Illinois +1 locations
Conditions: Stroke, Acute
Register for Updates